Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.VBL Therapeutics has presented the preclinical data of VB-111, a dual-action, anti-angiogenic and vascular disruptive agent (VDA) that utilizes VBL’s proprietary platform technology Vascular Targeting System (VTS) for cancer therapy.
Subscribe to our email newsletter
The first trail results showed that VB-111 was safe and specific and may offer additive effect to chemotherapy.
In the trial, the researchers investigated the safety and efficacy of VB-111 as monotherapy, in combination with bevacizumab and in combination with carboplatin and pemetrexed in a Lewis Lung metastasis model and found that VB-111 induced a dose-dependent tumor reduction of up to 90%.
However, in the second study, VB-111 stands as a promising candidate as a treatment for glioblastoma.
The second trial examined the impact of VB-111 on tumor growth in rats with established intracranial xenografts.
The results demonstrated decreased tumor size in animals treated with VB-111, with those rats showing a median survival of 48 days, versus 38 days for untreated rats.